title: Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity.
abstract: Endothelial cell receptors for the angiostatic chemokines IFN-gamma-inducible protein of 10 kDa (IP-10) and monokine induced by IFN-gamma (Mig) have not yet been identified, and the mechanisms responsible for the effects of these chemokines on angiogenesis are still unclear. IP-10 and Mig share a common functional receptor on activated T lymphocytes, named CXC chemokine receptor 3 (CXCR3). Using in situ hybridization and immunohistochemistry, we show that CXCR3 is expressed by a small percentage of microvascular endothelial cells in several human normal and pathological tissues. Primary cultures of human microvascular endothelial cells (HMVECs) likewise express CXCR3, although this expression is limited to the S/G2-M phase of their cell cycle. Both IP-10 and Mig, as well as the IFN-gamma-inducible T-cell alpha chemoattractant (I-TAC), which all share high-affinity binding for CXCR3, block HMVEC proliferation in vitro, an effect that can be inhibited by an anti-CXCR3 antibody. These data provide definitive evidence of CXCR3 expression by HMVEC and open new avenues for therapeutic interventions in all conditions in which an angiostatic effect may be beneficial.
authors.affiliation: Department of Clinical Pathophysiology, Endocrinology Unit, University of Florence, Florence, Italy. promagnani@iol.it
authors.forename: P
authors.initials: P
authors.lastname: Romagnani
authors.forename: F
authors.initials: F
authors.lastname: Annunziato
authors.forename: L
authors.initials: L
authors.lastname: Lasagni
authors.forename: E
authors.initials: E
authors.lastname: Lazzeri
authors.forename: C
authors.initials: C
authors.lastname: Beltrame
authors.forename: M
authors.initials: M
authors.lastname: Francalanci
authors.forename: M
authors.initials: M
authors.lastname: Uguccioni
authors.forename: G
authors.initials: G
authors.lastname: Galli
authors.forename: L
authors.initials: L
authors.lastname: Cosmi
authors.forename: L
authors.initials: L
authors.lastname: Maurenzig
authors.forename: M
authors.initials: M
authors.lastname: Baggiolini
authors.forename: E
authors.initials: E
authors.lastname: Maggi
authors.forename: S
authors.initials: S
authors.lastname: Romagnani
authors.forename: M
authors.initials: M
authors.lastname: Serio
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D002453:Cell Cycle; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D054357:Chemokine CXCL10; D054371:Chemokine CXCL11; D054370:Chemokine CXCL9; D019743:Chemokines, CXC / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D015870:Gene Expression; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D018919:Neovascularization, Physiologic; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: D020533:Angiogenesis Inhibitors; C515202:CXCL11 protein, human; C080810:CXCL9 protein, human; C515187:CXCR3 protein, human; D054357:Chemokine CXCL10; D054371:Chemokine CXCL11; D054370:Chemokine CXCL9; D019743:Chemokines, CXC; D036341:Intercellular Signaling Peptides and Proteins; D012333:RNA, Messenger; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine